Dexilant SoluTab delayed-release tablets (dexlansoprazole) approved by FDA for GERD- Takeda

Takeda Pharmaceuticals announced that the FDA approved Dexilant SoluTab delayed-release orally disintegrating tablets, a new formulation of dexlansoprazole that can be taken by allowing the tablet to melt in the patient's mouth. Dexilant SoluTab is a proton pump inhibitor (PPI) indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) and the maintenance of healed erosive esophagitis (EE) and relief of heartburn in adults 18 years and older. Dexilant SoluTab is a PPI with dual delayed release (DDR) technology that is designed to provide two separate releases of medication.

Dexilant (dexlansoprazole) 30 mg and 60 mg delayed-release capsules are indicated for healing all grades of erosive esophagitis (EE) for up to 8 weeks, for maintaining healing of EE and relief of heartburn for up to 6 months, and for treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for 4 weeks.